0001070081-23-000028 | 10-Q | XBRL Viewer

March 31, 2023

Less Than

More Than

12 Months

12 Months

Corporate debt securities

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 167,495	$ 279,834
Marketable securities	118,808	130,871
Trade and royalty receivables, net	201,867	155,614
Inventory, net	26,649	21,808
Prepaid expenses and other current assets	98,573	105,658
Total current assets	613,392	693,785
Fixed assets, net	79,492	72,590
Intangible assets, net	686,205	705,891
Goodwill	82,341	82,341
Operating lease ROU assets	99,531	102,430
Deposits and other assets	47,878	48,582
Total assets	1,608,839	1,705,619
Current liabilities:
Accounts payable and accrued expenses	332,091	320,366
Deferred revenue	214	1,351
Operating lease liabilities- current	9,598	9,370
Finance lease liabilities- current	1,857	3,000
Liability for sale of future royalties - current	97,874	72,149
Total current liabilities	441,634	406,236
Long-term debt	572,091	571,722
Contingent consideration payable	166,400	164,000
Deferred tax liability	102,831	102,834
Operating lease liabilities- noncurrent	100,442	100,860
Finance lease liabilities- noncurrent	17,184	18,675
Liability for sale of future royalties- noncurrent	665,677	685,737
Other long-term liabilities	141	2,641
Total liabilities	2,066,400	2,052,705
Stockholders' deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 74,012,034 shares at March 31, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022	73	72
Additional paid-in capital	2,339,886	2,305,020
Accumulated other comprehensive (loss) income	(1,587)	4,796
Accumulated deficit	(2,795,933)	(2,656,974)
Total stockholders' deficit	(457,561)	(347,086)
Total liabilities and stockholders' deficit	$ 1,608,839	$ 1,705,619

Intangible assets and goodwill - (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of definite lived intangible assets

Definite lived intangible assets consisted of the following at March 31, 2023 and December 31, 2022:


		Ending Balance at				Reclass from				Foreign		Ending Balance at
Definite lived		December 31,				Indefinite Lived to				currency		March 31,
intangibles assets, gross		2022		Additions		Definite Lived		Impairment		translation		2023
Emflaza	$	420,253	$	17,515		—		—		—	$	437,768
Waylivra		9,316		—		—		—		170		9,486
Tegsedi		7,109		2,001		—		—		131		9,241
Upstaza		89,550		—		—		—		—		89,550
Total definite lived intangibles, gross	$	526,228	$	19,516	$	—	$	—	$	301	$	546,045


		Ending Balance at				Foreign		Ending Balance at
Definite lived		December 31,				currency		March 31,
intangibles assets, accumulated amortization		2022		Amortization		translation		2023
Emflaza	$	(266,023)	$	(36,996)	$	—	$	(303,019)
Waylivra		(2,751)		(261)		(52)		(3,064)
Tegsedi		(1,709)		(292)		(36)		(2,037)
Upstaza		(3,420)		(1,866)		—		(5,286)
Total definite lived intangibles, accumulated amortization	$	(273,903)	$	(39,415)	$	(88)	$	(313,406)

Total definite lived intangibles, net							$	232,639

Schedule of estimated future amortization of intangible assets


	As of March 31, 2023
2023	$	118,266
2024		33,462
2025		9,702
2026		9,702
2027 and thereafter		61,507
Total	$	232,639

Schedule of indefinite lived intangible assets

Indefinite lived intangible assets consisted of the following at March 31, 2023 and December 31, 2022:


		Ending Balance at				Reclass from				Foreign		Ending Balance at
Indefinite lived		December 31,				Indefinite Lived to				currency		March 31,
intangibles assets		2022		Additions		Definite Lived		Impairment		translation		2023
Upstaza	$	235,766	$	—	$	—	$	—	$	—	$	235,766
PTC-FA		112,500		—		—		—		—		112,500
PTC-AS		105,300		—		—		—		—		105,300
Total indefinite lived intangibles	$	453,566	$	—	$	—	$	—	$	—	$	453,566

Total intangible assets, net											$	686,205

Leases - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
Leases - Narrative (Details) $ in Thousands	Jul. 01, 2020 USD ($) ft² item	May 31, 2022 USD ($) ft² period building	Mar. 31, 2023 USD ($) lease	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Jun. 19, 2020 USD ($)
Leases
Number of operating leases \| lease			2
Operating lease, expense			$ 7,100	$ 5,300
Finance Lease, Liability			19,041
Finance lease liabilities- current			1,857			$ 3,000
Finance lease liabilities- noncurrent			17,184			18,675
Aggregate rent, Initial term			264,252
Operating lease ROU assets			99,531			$ 102,430
Operating Lease, Liability			110,040
Research and development			195,124	140,078
2024			18,465
MassBio
Leases
Finance lease cost			400	$ 400
Finance Lease, Liability							$ 41,400
Finance lease liabilities- current			1,800
Finance lease liabilities- noncurrent			$ 17,200
Finance lease ROU asset							$ 41,400
Finance lease, term of contract							12 years 6 months
Research and development					$ 41,400
Minimum
Leases
Operating lease, term of contract			10 months 24 days
Maximum
Leases
Operating lease, term of contract			16 years 2 months 12 days
Renewal term			20 years
Hopewell Campus
Leases
Operating lease, term of contract	15 years
Area of real estate property \| ft²	220,500
Renewal term	10 years
Number of renewable terms \| item	2
Lessee, Operating Lease, Existence of Option to Extend [true false]	true
Aggregate rent, Initial term	$ 111,500
Percent of market rate	95.00%
Warren Premises
Leases
Operating lease, term of contract		17 years
Number of buildings leased \| building		2
Area of real estate property \| ft²		360,000
Renewal term		5 years
Number of renewable terms \| period		3
Lessee, Operating Lease, Existence of Option to Extend [true false]		true
Aggregate rent, Initial term		$ 163,000
Operating lease ROU assets		28,900
Operating Lease, Liability		$ 28,900
Base rent abatement period		3 years
Base rent abatement		$ 18,600
Aggregate rent net of base rate abatement, initial term		144,400
Allowance for lease improvements		36,200
Commitment to fund construction account		3,600
Payment due from lessor at issuance of temporary certificate of occupancy		$ 5,000

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	Apr. 25, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-35969
Entity Registrant Name	PTC Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3416587
Entity Address, Address Line One	100 Corporate Court
Entity Address, City or Town	South Plainfield
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07080
City Area Code	908
Local Phone Number	222-7000
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	PTCT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,190,700
Entity Central Index Key	0001070081
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Revenue	$ 220,382	$ 148,735
Operating expenses:
Cost of product sales, excluding amortization of acquired intangible assets	14,144	10,135
Amortization of intangible assets	39,415	23,473
Research and development	195,124	140,078
Selling, general and administrative	86,914	73,271
Change in the fair value of deferred and contingent consideration	2,400	(11,700)
Total operating expenses	337,997	235,257
Loss from operations	(117,615)	(86,522)
Interest expense, net	(27,331)	(23,514)
Other income (expense), net	9,956	(11,855)
Loss before income tax expense	(134,990)	(121,891)
Income tax expense	(3,969)	(4,835)
Net loss attributable to common stockholders	$ (138,959)	$ (126,726)
Weighted-average shares outstanding:
Basic	73,729,284	71,215,105
Diluted	73,729,284	71,215,105
Net loss per share-basic and diluted (in dollars per share)
Basic	$ (1.88)	$ (1.78)
Diluted	$ (1.88)	$ (1.78)
Net product revenue
Revenues:
Revenue	$ 187,557	$ 129,832
Collaboration revenue
Revenues:
Revenue	6	7
Royalty revenue
Revenues:
Revenue	30,831	18,896
Manufacturing revenue
Revenues:
Revenue	$ 1,988	$ 0

Stock award plan - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended
	Jun. 08, 2022	Dec. 31, 2022	Dec. 31, 2020	Jun. 30, 2016	Mar. 31, 2023	Mar. 31, 2022	Apr. 30, 2022	Jun. 30, 2021	May 31, 2021	Jan. 31, 2020
Stock option plan
Share-based compensation expense					$ 28,815	$ 26,589
Unrecognized compensation cost					$ 238,400
Weighted average remaining service period for recognition of unrecognized compensation cost					2 years 4 months 20 days
Stock option
Stock option plan
Granted (in shares)					863,410
Forfeited (in shares)					53,716
Expected dividend yield (as a percent)					0.00%
Weighted average grant date fair value (in dollars per share)					$ 21.18
Restricted stock units
Stock option plan
Granted (in shares)					1,861,235
Employee Stock Purchase Plan
Stock option plan
Number of shares authorized (in shares)								2,000,000	1,000,000
Award requisite service period				6 months
Purchase price of common stock, percent				85.00%
Employee stock purchase plan, voting percentage limit				5.00%
Share-based compensation expense					$ 700
1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan \| Common stock
Stock option plan
Number of shares available for issuance					0
Amended 2013 LTIP
Stock option plan
Number of shares available for issuance					6,598,348
Number of additional shares authorized (in shares)	8,475,000
Amended 2013 LTIP \| Maximum
Stock option plan
Number of shares authorized (in shares)	16,724,212
2020 Inducement Stock Incentive Plan
Stock option plan
Vesting period					4 years
2020 Inducement Stock Incentive Plan \| Maximum
Stock option plan
Expiration period					10 years
2020 Inducement Stock Incentive Plan \| Common stock
Stock option plan
Number of shares available for issuance					1,699,326
Number of additional shares authorized (in shares)		1,700,000	1,000,000
2020 Inducement Stock Incentive Plan \| Common stock \| Maximum
Stock option plan
Number of shares authorized (in shares)							1,300,000			1,000,000
2020 Inducement Stock Incentive Plan \| Stock option
Stock option plan
Stockholder's specified ownership percentage					10.00%
Inducement grants for non-statutory stock options (in shares)					98,050
2020 Inducement Stock Incentive Plan \| Stock option \| Minimum
Stock option plan
Stock options granted, exercise price as percentage of the fair market value of common stock at grant date					100.00%
2020 Inducement Stock Incentive Plan \| Stock option \| Maximum
Stock option plan
Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market value of common stock at grant date					110.00%
2020 Inducement Stock Incentive Plan \| Restricted stock units
Stock option plan
Granted (in shares)					42,755

Net loss per share - Numerator and Denominator (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net loss - Basic	$ (138,959)	$ (126,726)
Net loss - Diluted	$ (138,959)	$ (126,726)
Denominator
Basic	73,729,284	71,215,105
Diluted	73,729,284	71,215,105
Net loss per share - Basic	$ (1.88)	$ (1.78)
Net loss per share - Diluted	$ (1.88)	$ (1.78)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Debt

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Debt

9. Debt

Liability for sale of future royalties

In July 2020, the Company entered into the Royalty Purchase Agreement. As RPI’s interest is explicitly limited, the $650.0 million cash consideration was classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470 and ASC 835. The initial annual effective interest rate was determined to be 11.0%. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI and updates the effective interest rate on a quarterly basis. Issuance costs related to the transaction were determined to be immaterial.

The following table shows the activity within the “liability for sale of future royalties- current” and “liability for sale of future royalties- noncurrent” accounts for the three months ended March 31, 2023:


	Three Months Ended March 31,
Liability for sale of future royalties- (current and noncurrent)	2023
Beginning balance as of December 31, 2022	$	757,886
Less: Non-cash royalty revenue payable to RPI		(13,237)
Plus: Non-cash interest expense recognized		18,902
Ending balance	$	763,551
Effective interest rate as of March 31, 2023		9.8	%

Non-cash interest expense is recorded in the statement of operations within “Interest expense, net”.

Senior Secured Term Loan

On October 27, 2022 (the “Closing Date”), the Company entered into a credit agreement (the “Blackstone Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requests such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the “Loan Parties”) and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, “Blackstone”, and such lenders, together with their permitted assignees, the “Lenders” and each a “Lender”) and Wilmington Trust, National Association, as the administrative agent for the Lenders.

The Blackstone Credit Agreement provides for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million (the “Initial Loans”) and a committed delayed draw term loan facility of up to $150.0 million (the “Delayed Draw Loans” and, together with the Initial Loans, the “Loans”) to be funded at the Company’s request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplates the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.

The Loans mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bear interest at a variable rate equal to, at the Company’s option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans are subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date of the applicable Loan funded.

All obligations under the Blackstone Credit Agreement are secured, subject to certain exceptions and specified inclusions, by security interests in certain assets of the Loan Parties, including (1) intellectual property and other assets related to Translarna, Emflaza, Upstaza, sepiapterin and, until certain release conditions are met, vatiquinone, in each case, together with any other forms, formulations, or methods of delivery of any such products, and regardless of trade or brand name, (2) future acquired intellectual property (but not internally developed intellectual property unrelated to other intellectual property collateral) and other related assets, and (3) the equity interests held by the Loan Parties in certain of their subsidiaries. The Blackstone Credit Agreement contains certain negative covenants with which the Company must remain in compliance. The Blackstone Credit Agreement also requires that the Company maintains consolidated liquidity of at least $100.0 million as of the last day of each fiscal quarter, which shall be increased to $200.0 million upon the Company consummating acquisitions meeting certain consolidated thresholds described therein. In addition, the Company will be required under conditions specified in the Blackstone Credit Agreement to fund a reserve account up to certain amounts specified therein, including $50.0 million that the Company funded into the reserve account during the quarter ended March 31, 2023. The funds in the reserve account are available to prepay the Loans at any time at the Company’s option, and are, if funded, subject to release upon certain further conditions. Upon any such release, such funds are freely available for use by the Company subject to the generally applicable terms and conditions of the Blackstone Credit Agreement. The Blackstone Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default.

The following table sets forth total interest expense recognized related to the senior secured term loan:


	Three Months Ended
	March 31,
	2023
Contractual interest expense	$	9,178
Amortization of debt issuance costs		150
Total	$	9,328
Effective interest rate		13.2	%

2026 Convertible Notes

In September 2019, the Company issued, at par value, $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by the Company.

The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").

Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances:

●

during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not

consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

●

during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;

●

during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or

●

upon the occurrence of specified corporate events.

On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or any combination thereof at the Company’s election.

The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company’s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of the Company’s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.

The Company is not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically.

If the Company undergoes a “fundamental change” (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company’s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company’s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

The 2026 Convertible Notes consist of the following:



	March 31, 2023		December 31, 2022
Principal	$	287,500	$	287,500
Less: Debt issuance costs		(4,168)		(4,456)
Net carrying amount	$	283,332	$	283,044

As of March 31, 2023, the remaining contractual life of the 2026 Convertible Notes is approximately 3.5 years.

The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:



	Three Months Ended March 31,
	2023			2022
Contractual interest expense	$	1,069		$	1,069
Amortization of debt issuance costs		288			283
Total	$	1,357		$	1,352
Effective interest rate		1.9	%		1.9	%

In April 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $2.1 million, for the period beginning September 25, 2020 and ending March 14, 2022. This amount is not included in the table above, but was recorded as interest expense, net within the statement of operations for the three months ended March 31, 2022.

2022 Convertible Notes

In August 2015, the Company issued, at par value, $150.0 million aggregate principal amount of 3.00% convertible senior notes due 2022, (the “2022 Convertible Notes”). On August 15, 2022, the Company repaid the outstanding principal amount and accrued interest, totaling $152.3 million, of the 2022 Convertible Notes that was due upon maturity in accordance with the terms of the notes.

The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:



	Three Months Ended March 31,
	2023			2022
Contractual interest expense	$	—		$	1,110
Amortization of debt issuance costs		—			181
Total	$	—		$	1,291
Effective interest rate		—	%		3.5	%

Commitments and contingencies - Narrative (Details) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	Apr. 29, 2020 USD ($)	Mar. 31, 2023 USD ($) D $ / shares	Jun. 30, 2016 USD ($)	Dec. 31, 2022 USD ($)	May 29, 2020 USD ($)
Other Commitments
Milestone payable		$ 32,500
Accrued royalties		32,694		$ 40,546
Wellcome Trust
Other Commitments
Development milestone payment obligations				2,500
Milestone obligation payments made			$ 800
Censa
Other Commitments
Milestone payable opted to be paid through issuance of common stock		$ 30,000
Weighted average stock price \| $ / shares		$ 44.9748
Consecutive trading days used in determining weighted average stock price \| D		30
Asset acquisition, development and regulatory milestones					$ 109,000
Asset acquisition, initial milestone					30,000
Censa \| Maximum
Other Commitments
Asset acquisition, milestone, amount					217,500
Asset acquisition, net sales milestone					$ 160,000
Censa \| Accounts payable and accrued expenses
Other Commitments
Milestone payable		$ 30,000
SMA License Agreement \| SMA Foundation
Other Commitments
Royalty expense		31,600
Royalty payments		24,500
Accrued royalties		7,100
SMA License Agreement \| SMA Foundation \| Maximum
Other Commitments
Potential royalty payments due on net product sales		52,500
Agilis
Other Commitments
Development milestone payments which the entity is obligated to pay	$ 40,000	40,000
Potential developmental and regulatory milestones		331,000
Potential sales milestones		150,000
Milestone obligation payments made				$ 50,000
Development milestone obligation payments made		$ 2,400
Agilis \| Minimum
Other Commitments
Product sales (as a percent)		2.00%
Agilis \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay		$ 60,000
Priority review voucher amount		535,000
Potential sales milestones		$ 150,000
Product sales (as a percent)		6.00%
Development milestone payment obligations, net of cancellation and forfeiture		$ 20,000
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture		361,000
Agilis \| Rights Exchange Agreement
Other Commitments
Contingent liability cancellation and forfeiture of potential milestone payments	174,000
Development milestone payment obligations, cancellation and forfeiture	37,600
Contingent liability, cancellation and forfeiture	$ 211,600
BioElectron \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay		200,000
Marathon \| Agilis Merger Agreement
Other Commitments
Milestone obligation payments made		50,000
Net product revenue \| Wellcome Trust \| Maximum
Other Commitments
Development milestone payments which the entity is obligated to pay		$ 14,500

Fair value of financial instruments and investments - (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis


	March 31, 2023
			Quoted prices		Significant
			in active		other		Significant
			markets for		observable		unobservable
			identical assets		inputs		inputs
	Total		(level 1)		(level 2)		(level 3)
Marketable securities - available for sale	$	10,249	$	—	$	10,249	$	—
Marketable securities - equity investments	$	108,559	$	108,559	$	—	$	—
ClearPoint Equity Investments	$	10,926	$	10,926	$	—	$	—
ClearPoint convertible debt security	$	15,290	$	—	$	15,290	$	—
Contingent consideration payable- development and regulatory milestones	$	85,500	$	—	$	—	$	85,500
Contingent consideration payable- net sales milestones and royalties	$	80,900	$	—	$	—	$	80,900


	December 31, 2022
			Quoted prices		Significant
			in active		other		Significant
			markets for		observable		unobservable
			identical assets		inputs		inputs
	Total		(level 1)		(level 2)		(level 3)
Marketable securities - available for sale	$	22,610	$	—	$	22,610	$	—
Marketable securities - equity investments	$	108,261	$	108,261	$	—	$	—
ClearPoint Equity Investments	$	10,965	$	10,965	$	—	$	—
ClearPoint convertible debt security	$	15,231	$	—	$	15,231	$	—
Contingent consideration payable- development and regulatory milestones	$	82,500	$	—	$	—	$	82,500
Contingent consideration payable- net sales milestones and royalties	$	81,500	$	—	$	—	$	81,500

Summary of marketable securities accounted for as available-for-sale debt securities


	March 31, 2023
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Corporate debt securities	$	10,689	$	—	$	(440)	$	10,249
Total	$	10,689	$	—	$	(440)	$	10,249


	December 31, 2022
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Commercial paper	$	12,419	$	5	$	—	$	12,424
Corporate debt securities		10,685		—		(499)		10,186
Total	$	23,104	$	5	$	(499)	$	22,610

Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position


	March 31, 2023
	Securities in an unrealized loss				Securities in an unrealized loss
	position less than 12 months				position greater than or equal to 12 months				Total
	Unrealized losses		Fair Value		Unrealized losses		Fair Value		Unrealized losses		Fair Value
Corporate debt securities	$	—		—		(440)		10,249		(440)	$	10,249
Total	$	—	$	—	$	(440)	$	10,249	$	(440)	$	10,249


	December 31, 2022
	Securities in an unrealized loss				Securities in an unrealized loss
	position less than 12 months				position greater than or equal to 12 months				Total
	Unrealized losses		Fair Value		Unrealized losses		Fair Value		Unrealized losses		Fair Value
Corporate debt securities	$	—		—		(499)		10,186		(499)	$	10,186
Total	$	—	$	—	$	(499)	$	10,186	$	(499)	$	10,186

Schedule of marketable securities on the balance sheet

Total

10,249

—


	December 31, 2022
	Less Than		More Than
	12 Months		12 Months
Commercial paper	$	12,424	$	—
Corporate debt securities		—		10,186
Total	$	12,424	$	10,186

Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable


	Level 3 liabilities
	Contingent consideration payable-		Contingent consideration payable-
	development and regulatory		net sales milestones and royalties
	milestones
Beginning balance as of December 31, 2022	$	82,500	$	81,500
Additions		—		—
Change in fair value		3,000		(600)
Payments		—		—
Ending balance as of March 31, 2023	$	85,500	$	80,900


	Level 3 liabilities
	Contingent consideration payable-		Contingent consideration payable-
	development and regulatory		net sales milestones and royalties
	milestones
Beginning balance as of December 31, 2021	$	139,300	$	100,600
Additions		—		—
Change in fair value		(4,600)		(7,100)
Payments		—		—
Ending balance as of March 31, 2022	$	134,700	$	93,500

Fair Value Measurement Inputs and Valuation Techniques


	March 31, 2023
	Fair Value	Valuation Technique	Unobservable Input	Range
Contingent consideration payable- development and regulatory milestones	$85,500	Probability-adjusted discounted cash flow	Potential development and regulatory milestones Probabilities of success Discount rates Projected years of payments	$0 - $331 million 25% - 92% 5.5% - 7.7% 2023 - 2029
Contingent considerable payable- net sales milestones and royalties	$80,900	Option-pricing model with Monte Carlo simulation	Potential net sales milestones Probabilities of success Potential percentage of net sales for royalties Discount rate Projected years of payments	$0 - $150 million 25% - 100% 2% - 6% 12% 2025 - 2041


	December 31, 2022
	Fair Value	Valuation Technique	Unobservable Input	Range
Contingent consideration payable- development and regulatory milestones	$82,500	Probability-adjusted discounted cash flow	Potential development and regulatory milestones Probabilities of success Discount rates Projected years of payments	$0 - $331 million 25% - 92% 6.2% - 8.3% 2023 - 2029
Contingent considerable payable- net sales milestones and royalties	$81,500	Option-pricing model with Monte Carlo simulation	Potential net sales milestones Probabilities of success Potential percentage of net sales for royalties Discount rate Projected years of payments	$0 - $150 million 25% - 100% 2% - 6% 11.5% 2025 - 2041

Commitments and contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and contingencies

10. Commitments and contingencies

Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company’s oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program. Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a

partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company’s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company made the first development milestone payment of $0.8 million to Wellcome Trust under the oncology platform funding agreement during the second quarter of 2016. During the year ended December 31, 2022, the Company incurred $2.5 million of development milestones in connection with the enrollment of patients in the registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS, which is recorded in accounts payable and accrued expenses on the balance sheet and will be payable upon the earlier to occur of the first dose administered to the last patient enrolled in the study or the termination of dosing of all patients in the study. Additional milestone payments of up to an aggregate of $14.5 million may become payable by the Company to Wellcome Trust under this agreement.

The Company has also entered into a collaboration agreement with the SMA Foundation. The Company is obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, with respect to collaboration products the Company outlicenses, including Evrysdi, a specified percentage of certain payments the Company receives from its licensee. Since inception, the SMA Foundation has earned $31.6 million, $24.5 million which was paid and $7.1 million which was accrued as of March 31, 2023. The Company’s obligation to make such payments would end upon the Company’s payment to the SMA Foundation of an aggregate of $52.5 million.

Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC) (“Marathon”), Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon received a $50.0 million sales-based milestone during the three months ended March 31, 2022.

Pursuant to the Agilis Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i) the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million, (ii) the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0 million, and (iv) a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the applicable milestones have been achieved.

Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders canceled and forfeited their rights under the Agilis Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the milestones are achieved.

The Rights Exchange Agreement has no effect on the Agilis Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders’ rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Agilis Merger Agreement remain in effect pursuant to their terms, including the Company’s obligation to pay up to an aggregate maximum amount of $20.0 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement while excluding the remaining $2.4 million milestone payment that was due and paid upon the passing of the second anniversary of the closing of the Agilis Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich

ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Agilis Merger Agreement.

In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. As a result of such approval, the Company paid the former equityholders of Agilis $50.0 million in accordance with the terms of the Agilis Merger Agreement in the year ended December 31, 2022. As of March 31, 2023, the remaining potential development and regulatory milestones is $331.0 million, and the remaining potential sales milestones is $150.0 million.

On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “BioElectron Asset Purchase Agreement”). BioElectron was a private company with a pipeline focused on inflammatory and central nervous system (CNS) disorders. The lead program, vatiquinone, is in late stage development for CNS disorders with substantial unmet need and significant commercial opportunity that are complementary to PTC’s existing pipeline.

Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company’s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones. Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.

Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the “Censa Merger Agreement”) by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the “Censa Merger”), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5 million for sepiapterin’s two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109.0 million in development and regulatory milestones for each additional indication of sepiapterin, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0 million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa’s intellectual property to commercialize sepiapterin, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. Pursuant to the Censa Merger Agreement, the Company has the option to pay the initial $30.0 million development milestone, for the completion of enrollment of a Phase 3 clinical trial for sepiapterin for PKU, if achieved, in cash or shares of the Company’s common stock.

In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU. The Company has decided to exercise its option to pay the $30.0 development milestone in shares of its common stock less any cash payments made to Censa securityholders who are not accredited investors, certain cash payments made to former Censa optionholders and cash in lieu of fractional shares as calculated in accordance with the Censa Merger Agreement. Pursuant to the Censa Merger Agreement, the shares of common stock will be issued at a price of $44.9748 per share, or the volume-weighted average price of the Company’s common stock on the Nasdaq Global Select Market for the 30 consecutive trading days immediately prior to the second business day prior to the date that the milestone was achieved. The $30.0 million development milestone is recorded in accounts payable and accrued expense on the Company's consolidated balance sheet as of March 31, 2023.

The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.

The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.

From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (138,959)	$ (126,726)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	42,825	26,314
Non-cash operating lease expense	2,942	1,908
Non-cash royalty revenue related to sale of future royalties	(13,237)	(8,113)
Non-cash interest expense on liability related to sale of future royalties	18,902	18,874
Change in valuation of deferred and contingent consideration	2,400	(11,700)
Unrealized loss (gain) on ClearPoint Equity Investments	39	1,049
Unrealized (gain) loss on ClearPoint convertible debt security	(59)	1,542
Unrealized (gain) loss on marketable securities - equity investments	(2,166)	6,477
Disposal of asset		79
Amortization of (discounts) premiums on investments, net	(85)	887
Deferred income taxes	(4)
Amortization of debt issuance costs	438	464
Share-based compensation expense	28,815	26,589
Unrealized foreign currency transaction (gains) losses, net	(10,057)	2,135
Changes in operating assets and liabilities:
Inventory, net	(4,612)	350
Prepaid expenses and other current assets	57,611	25,118
Trade and royalty receivables, net	(43,426)	(28,372)
Deposits and other assets	743	(510)
Accounts payable and accrued expenses	33,524	(30,680)
Other liabilities	(3,988)	(3,089)
Deferred revenue	(1,137)
Net cash used in operating activities	(29,491)	(97,404)
Cash flows from investing activities
Purchases of fixed assets	(10,270)	(9,312)
Purchases of marketable securities - available for sale		(39,035)
Sale and redemption of marketable securities- available for sale	12,500	167,101
Sale and redemption of marketable securities - equity investments	2,196	2,423
Acquisition of product rights and licenses	(33,397)	(72,134)
Net cash (used in) provided by investing activities	(28,971)	49,043
Cash flows from financing activities
Proceeds from exercise of options	5,655	2,444
Debt issuance costs related to secured term loan	(182)
Payment of finance lease principal	(1,379)	(1,276)
Net cash provided by financing activities	4,094	1,168
Effect of exchange rate changes on cash	(7,963)	1,653
Net decrease in cash and cash equivalents	(62,331)	(45,540)
Cash and cash equivalents, and restricted cash beginning of period	295,925	197,218
Cash and cash equivalents, and restricted cash end of period	233,594	151,678
Supplemental disclosure of cash information
Cash paid for interest	12,956	6,130
Cash paid for income taxes	2,215	1,987
Supplemental disclosure of non-cash investing and financing activity
Unrealized gain (loss) on marketable securities, net of tax	54	(2,913)
Right-of-use assets obtained in exchange for operating lease obligations		587
Acquisition of product rights and licenses	19,406	$ 12,589
Debt issuance costs related to senior secured term loan	45
Capital expenditures unpaid at the end of period	28
Milestone payable	$ 32,500

Summary of significant accounting policies - Narrative (Details) $ in Thousands		1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 22, 2017	Jun. 30, 2022 USD ($)	Jul. 31, 2020 USD ($)	Mar. 31, 2023 USD ($) segment country	Mar. 31, 2022 USD ($) segment country	Dec. 31, 2019 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2018 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Credit agreement reserve				$ 50,000
Number of operating segments \| segment				1	1
Allowance for credit loss				$ 0	$ 0
Increase in allowance for credit losses				0	0
Allowance for doubtful accounts receivable				400			$ 300
Revenue				220,382	$ 148,735
Cash consideration received from Royalty Purchase Agreement			$ 650,000
Income taxes
Federal income tax statutory rate	21.00%
Federal income tax provision - IRC Section 174 R&D Expenses				700
State income tax provision - IRC Section 174 R&D Expenses				2,900
Agilis
Income taxes
Deferred tax liability								$ 122,000
Deposits and other assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Bank guarantee				500
Blackstone Credit Agreement
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Credit agreement reserve				$ 50,000
Hopewell Campus
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Period after which letter of credit may be reduced if lease is not in default						5 years
Hopewell Campus \| Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Term for letter of credit (in years)						5 years
Hopewell Campus \| Deposits and other assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Letters of credit						$ 7,500
Hopewell Campus \| Fifth Anniversary
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Letters of credit						$ 3,800
Warren Premises
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Period after which letter of credit may be reduced if lease is not in default		5 years
Warren Premises \| Deposits and other assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Letters of credit		$ 8,100
Warren Premises \| Fifth Anniversary
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Letters of credit		$ 4,100
Net product revenue \| Geographic concentration risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of countries exceeding 10% of net product sales \| country				3	2
Percentage of net product sales threshold				10.00%	10.00%
Net product revenue \| Geographic concentration risk \| Russia
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				$ 44,600
Net product revenue \| Geographic concentration risk \| Brazil
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				25,900	$ 25,800
Net product revenue \| Geographic concentration risk \| United States
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				54,600	48,600
Net product revenue
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				187,557	129,832
Net product revenue \| Non-US
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				133,000	81,200
Emflaza \| United States
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				54,600	48,600
Translarna \| Non-US
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue				$ 115,100	$ 79,200

Debt - Senior Secured Term Loan (Details) - USD ($) $ in Thousands		3 Months Ended
	Oct. 27, 2022	Mar. 31, 2023	Mar. 31, 2022	Jul. 31, 2020
Debt Facility
Credit agreement reserve		$ 50,000
Interest expense
Amortization of debt issuance costs		$ 438	$ 464
Effective interest rate		9.80%		11.00%
Blackstone Credit Agreement
Debt Facility
Maximum borrowing capacity	$ 950,000
Debt issuance costs capitalized	11,600
Credit agreement reserve		$ 50,000
Interest expense
Contractual interest expense		9,178
Amortization of debt issuance costs		150
Total		$ 9,328
Effective interest rate		13.20%
Blackstone Credit Agreement \| Minimum
Debt Facility
Minimum consolidated liquidity covenant	100,000
Increased minimum consolidated liquidity covenant after consummation of acquisitions meeting specified thresholds	$ 200,000
Blackstone Credit Agreement \| Adjusted Term SOFR
Debt Facility
Basis spread on variable rate	7.25%
Floor interest rate	1.00%
Blackstone Credit Agreement \| Base Rate
Debt Facility
Basis spread on variable rate	6.25%
Floor interest rate	2.00%
Committed Loan Facility
Debt Facility
Maximum borrowing capacity	$ 450,000
Fund draw term	18 months
Loan term	7 years
Senior Secured Term Loan Facility
Debt Facility
Principal	$ 300,000
Committed Delayed Draw Term Loan Facility
Debt Facility
Maximum borrowing capacity	150,000
Uncommitted Incremental Facility
Debt Facility
Maximum borrowing capacity	$ 500,000

Fair value of financial instruments and investments

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Fair value of financial instruments and investments

4. Fair value of financial instruments and marketable securities

The Company follows the fair value measurement rules, which provideguidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities.

This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

●

Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.

●

Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

●

Level 3—Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.

Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.

The Company owns common stock in ClearPoint Neuro, Inc. (“ClearPoint”) (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the “ClearPoint Equity Investments”) represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint Equity Investments are components of deposits and other assets on the consolidated balance sheet. During the three months ended March 31, 2023 and 2022, the Company recorded unrealized losses of $0.1 million and $1.0 million, respectively. These unrealized losses are components of other income (expense), net within the consolidated statement of operations. The fair value of the ClearPoint Equity Investments was $10.9 million and $11.0 million as of March 31, 2023 and December 31, 2022, respectively. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.

In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date. The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825. The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three months ended March 31, 2023 and 2022, the Company recorded unrealized gains of $0.1 million and unrealized losses of $1.5 million, respectively. These unrealized gains and losses are components of other income (expense), net within the consolidated statement of operations. The fair value of the convertible debt security was $15.3 million and $15.2 million as of March 31, 2023 and December 31, 2022, respectively. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the ClearPoint Equity Investments and the ClearPoint convertible debt security, no other items included in deposits and other assets on the consolidated balance sheets are fair valued.

The Company has investments in mutual funds, including one that is denominated in a foreign currency. All of these are equity investments and are classified as marketable securities on the Company’s consolidated balance sheets. These equity investments are reported at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are included as components of other income (expense), net within the consolidated statement of operations. For the three months ended March 31, 2023 and 2022, the Company had unrealized gains of $2.2 million and unrealized losses of $6.5 million relating to the equity investments still held at the reporting date, respectively. For the three months ended March 31, 2023 and 2022, the Company had redemptions of $2.2

million and $2.4 million, respectively. For the three months ended March 31, 2023 and 2022, the Company had foreign currency unrealized gains of $0.3 million and $0.7 million, respectively, relating to these equity investments.

Fair value of marketable securities that are classified as available for sale debt securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining available for sale debt securities, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.

The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022:


	March 31, 2023
			Quoted prices		Significant
			in active		other		Significant
			markets for		observable		unobservable
			identical assets		inputs		inputs
	Total		(level 1)		(level 2)		(level 3)
Marketable securities - available for sale	$	10,249	$	—	$	10,249	$	—
Marketable securities - equity investments	$	108,559	$	108,559	$	—	$	—
ClearPoint Equity Investments	$	10,926	$	10,926	$	—	$	—
ClearPoint convertible debt security	$	15,290	$	—	$	15,290	$	—
Contingent consideration payable- development and regulatory milestones	$	85,500	$	—	$	—	$	85,500
Contingent consideration payable- net sales milestones and royalties	$	80,900	$	—	$	—	$	80,900


	December 31, 2022
			Quoted prices		Significant
			in active		other		Significant
			markets for		observable		unobservable
			identical assets		inputs		inputs
	Total		(level 1)		(level 2)		(level 3)
Marketable securities - available for sale	$	22,610	$	—	$	22,610	$	—
Marketable securities - equity investments	$	108,261	$	108,261	$	—	$	—
ClearPoint Equity Investments	$	10,965	$	10,965	$	—	$	—
ClearPoint convertible debt security	$	15,231	$	—	$	15,231	$	—
Contingent consideration payable- development and regulatory milestones	$	82,500	$	—	$	—	$	82,500
Contingent consideration payable- net sales milestones and royalties	$	81,500	$	—	$	—	$	81,500

No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended March 31, 2023 and December 31, 2022.

The following is a summary of marketable securities accounted for as available for sale debt securities at March 31, 2023 and December 31, 2022:


	March 31, 2023
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Corporate debt securities	$	10,689	$	—	$	(440)	$	10,249
Total	$	10,689	$	—	$	(440)	$	10,249


	December 31, 2022
	Amortized		Gross Unrealized
	Cost		Gains		Losses		Fair Value
Commercial paper	$	12,419	$	5	$	—	$	12,424
Corporate debt securities		10,685		—		(499)		10,186
Total	$	23,104	$	5	$	(499)	$	22,610

For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. For the three months ended March 31, 2023 and 2022, no write downs occurred. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three months ended March 31, 2023 and 2022, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders’ equity.

For the three months ended March 31, 2023, the Company did not have any realized gains or losses from the sale of available for sale debt securities. For the three months ended March 31, 2022, the Company had $0.1 million realized losses from the sale of available for sale debt securities. Realized gains and losses are reported as a component of interest expense, net in the consolidated statement of operations. Reclassified amounts from other comprehensive items were determined using the actual realized gains and losses from the sales of marketable securities.

The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of March 31, 2023 are as follows:


	March 31, 2023
	Securities in an unrealized loss				Securities in an unrealized loss
	position less than 12 months				position greater than or equal to 12 months				Total
	Unrealized losses		Fair Value		Unrealized losses		Fair Value		Unrealized losses		Fair Value
Corporate debt securities	$	—		—		(440)		10,249		(440)	$	10,249
Total	$	—	$	—	$	(440)	$	10,249	$	(440)	$	10,249


	December 31, 2022
	Securities in an unrealized loss				Securities in an unrealized loss
	position less than 12 months				position greater than or equal to 12 months				Total
	Unrealized losses		Fair Value		Unrealized losses		Fair Value		Unrealized losses		Fair Value
Corporate debt securities	$	—		—		(499)		10,186		(499)	$	10,186
Total	$	—	$	—	$	(499)	$	10,186	$	(499)	$	10,186

Available for sale debt securities at March 31, 2023 and December 31, 2022 mature as follows:

Total

10,249

—


	December 31, 2022
	Less Than		More Than
	12 Months		12 Months
Commercial paper	$	12,424	$	—
Corporate debt securities		—		10,186
Total	$	12,424	$	10,186

The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations.

Convertible senior notes

In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September 15, 2026 (the “2026 Convertible Notes,”). The fair value of the 2026 Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the 2026 Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the 2026 Convertible Notes at March 31, 2023 and December 31, 2022 was $326.2 million and $281.7 million, respectively.

Level 3 valuation

The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of deferred and contingent consideration on the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company’s estimated development timelines for the acquired product candidate. On March 31, 2023, the weighted average discount rate for the development and regulatory milestones was 7.2% and the weighted average probability of success was 35%. The fair value of the net sales milestones and royalties is determined utilizing an option pricing model with Monte Carlo simulation to simulate a range of possible payment scenarios, and the average of the payments in these scenarios is then discounted to calculate present fair value. On March 31, 2023, the weighted average discount rate for the net sales milestones and royalties was 12.0% and the weighted average probability of success for the net sales milestones was 50%.

The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuations for the contingent consideration payable for the three months ended March 31, 2023 and March 31, 2022:


	Level 3 liabilities
	Contingent consideration payable-		Contingent consideration payable-
	development and regulatory		net sales milestones and royalties
	milestones
Beginning balance as of December 31, 2022	$	82,500	$	81,500
Additions		—		—
Change in fair value		3,000		(600)
Payments		—		—
Ending balance as of March 31, 2023	$	85,500	$	80,900


	Level 3 liabilities
	Contingent consideration payable-		Contingent consideration payable-
	development and regulatory		net sales milestones and royalties
	milestones
Beginning balance as of December 31, 2021	$	139,300	$	100,600
Additions		—		—
Change in fair value		(4,600)		(7,100)
Payments		—		—
Ending balance as of March 31, 2022	$	134,700	$	93,500

The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended March 31, 2023 and December 31, 2022:


	March 31, 2023
	Fair Value	Valuation Technique	Unobservable Input	Range
Contingent consideration payable- development and regulatory milestones	$85,500	Probability-adjusted discounted cash flow	Potential development and regulatory milestones Probabilities of success Discount rates Projected years of payments	$0 - $331 million 25% - 92% 5.5% - 7.7% 2023 - 2029
Contingent considerable payable- net sales milestones and royalties	$80,900	Option-pricing model with Monte Carlo simulation	Potential net sales milestones Probabilities of success Potential percentage of net sales for royalties Discount rate Projected years of payments	$0 - $150 million 25% - 100% 2% - 6% 12% 2025 - 2041


	December 31, 2022
	Fair Value	Valuation Technique	Unobservable Input	Range
Contingent consideration payable- development and regulatory milestones	$82,500	Probability-adjusted discounted cash flow	Potential development and regulatory milestones Probabilities of success Discount rates Projected years of payments	$0 - $331 million 25% - 92% 6.2% - 8.3% 2023 - 2029
Contingent considerable payable- net sales milestones and royalties	$81,500	Option-pricing model with Monte Carlo simulation	Potential net sales milestones Probabilities of success Potential percentage of net sales for royalties Discount rate Projected years of payments	$0 - $150 million 25% - 100% 2% - 6% 11.5% 2025 - 2041

The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock award plan - Stock Option Activity (Details) - Stock option $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Number of options
Outstanding at the beginning of the period (in shares) \| shares	11,502,417
Granted (in shares) \| shares	863,410
Exercised (in shares) \| shares	(211,561)
Forfeited/Cancelled (in shares) \| shares	(53,716)
Outstanding at the end of the period (in shares) \| shares	12,100,550
Vested or Expected to vest at the end of the period (in shares) \| shares	3,387,505
Exercisable at the end of the period (in shares) \| shares	8,348,132
Weighted- average exercise price
Outstanding at the beginning of the period (in dollars per share) \| $ / shares	$ 43.33
Granted (in dollars per share) \| $ / shares	39.93
Exercised (in dollars per share) \| $ / shares	28.61
Forfeited/Cancelled (in dollars per share) \| $ / shares	52.25
Outstanding at the end of the period (in dollars per share) \| $ / shares	43.30
Vested or Expected to vest at the end of the period (in dollars per share) \| $ / shares	47.15
Exercisable at the end of the period (in dollars per share) \| $ / shares	$ 41.68
Weighted- average remaining contractual term
Outstanding at the end of the period	6 years 4 months 17 days
Vested or Expected to vest at the end of the period	8 years 5 months 8 days
Exercisable at the end of the period	5 years 5 months 8 days
Aggregate intrinsic value (in thousands)
Outstanding at the end of the period (in dollars) \| $	$ 102,959
Vested or Expected to vest at the end of the period (in dollars) \| $	19,149
Exercisable at the end of the period (in dollars) \| $	$ 81,335

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (138,959)	$ (126,726)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	54	(2,913)
Foreign currency translation (loss) gain, net of tax	(6,437)	8,587
Comprehensive loss	$ (145,342)	$ (121,052)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Common stock	Additional paid-in capital	Accumulated other comprehensive (loss) income	Accumulated deficit	Total
Balance (in shares) at Dec. 31, 2021	70,828,226
Balance at the beginning of the period at Dec. 31, 2021	$ 71	$ 2,123,606	$ (24,282)	$ (2,097,957)	$ 1,438
Increase (Decrease) in Stockholders' Equity
Exercise of options (in shares)	97,188
Exercise of options		2,444			2,444
Restricted stock vesting and issuance (in shares)	411,627
Share-based compensation expense		26,589			26,589
Net loss				(126,726)	(126,726)
Comprehensive income (loss)			5,674		5,674
Balance (in shares) at Mar. 31, 2022	71,337,041
Balance at the end of the period at Mar. 31, 2022	$ 71	2,152,639	(18,608)	(2,224,683)	(90,581)
Balance (in shares) at Dec. 31, 2022	73,104,692
Balance at the beginning of the period at Dec. 31, 2022	$ 72	2,305,020	4,796	(2,656,974)	(347,086)
Increase (Decrease) in Stockholders' Equity
Exercise of options (in shares)	211,561
Exercise of options		5,655			5,655
Restricted stock vesting and issuance (in shares)	695,781
Restricted stock vesting and issuance, net	$ 1				1
Share-based compensation expense		28,815			28,815
Receivable from investor		396			396
Net loss				(138,959)	(138,959)
Comprehensive income (loss)			(6,383)		(6,383)
Balance (in shares) at Mar. 31, 2023	74,012,034
Balance at the end of the period at Mar. 31, 2023	$ 73	$ 2,339,886	$ (1,587)	$ (2,795,933)	$ (457,561)

Summary of significant accounting policies

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Summary of significant accounting policies

2. Summary of significant accounting policies

The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company’s audited financial statements as of December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 21, 2023 (the "2022 Form 10-K"). Selected significant accounting policies are discussed in further detail below.

Basis of presentation

The accompanying financial information as of March 31, 2023 and for the three months ended March 31, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.

In the opinion of management, the unaudited financial information as of March 31, 2023 and for the three months ended March 31, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair

statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.

Restricted cash

Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the letter of credit. Restricted cash also includes a bank guarantee of $0.5 million denominated in a foreign currency. Restricted cash also contains $50.0 million relating to funding the reserve account pursuant to the Blackstone Credit Agreement (as defined herein). This amount is included in prepaid and other current assets on the consolidated balance sheet. Refer to Note 9 for further details.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:


	End of			Beginning of
	period-		period-
	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	167,495	$	279,834
Restricted cash noncurrent included in deposits and other assets		16,099		16,091
Restricted cash current included in prepaid expenses and other current assets		50,000		—
Total Cash, cash equivalents and restricted cash per statement of cash flows	$	233,594	$	295,925

Marketable securities

The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating

agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three months ended March 31, 2023 and 2022, no allowance was recorded for credit losses.

Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.

Inventory and cost of product sales

Inventory

Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.

The following table summarizes the components of the Company’s inventory for the periods indicated:


	March 31, 2023		December 31, 2022
Raw materials	$	1,097	$	1,078
Work in progress		18,438		14,074
Finished goods		7,114		6,656
Total inventory	$	26,649	$	21,808

The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended March 31, 2023 and 2022, the Company recorded inventory write-downs of $0.1 million and $0.6 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three months ended March 31, 2023 and 2022, these amounts were immaterial.

Cost of product sales

Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.

Revenue recognition

Net product revenue

The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when

its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.

The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.

For the three months ended March 31, 2023 and 2022, net product sales outside of the United States were $133.0 million and $81.2 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $115.1 million and $79.2 million of the net product sales outside of the United States for the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023 and 2022, net product sales in the United States were $54.6 million and $48.6 million, respectively, consisting solely of sales of Emflaza. During the three months ended March 31, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $54.6 million, $44.6 million, and $25.9 million of net product sales, respectively. During the three months ended March 31, 2022, two countries, the United States and Brazil, accounted for at least 10% of the Company’s net product sales, representing $48.6 million and $25.8 million of net product sales, respectively.

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.

Collaboration and royalty revenue

The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.

At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.

For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined

not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.

For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.

The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.

For the three months ended March 31, 2023 and 2022, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.

For the three months ended March 31, 2023 and 2022, the Company has recognized $30.8 million and $18.9 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.

Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.

Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings.

For the three months ended March 31, 2023, the Company recognized $2.0 million of manufacturing revenue related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three months ended March 31, 2022. As of March 31, 2023 and December 31, 2022, the aggregate amount of transaction price

allocated to remaining performance obligations related to plasmid DNA and AAV vector production for external customers is $0.2 million and $1.4 million, respectively.

Allowance for doubtful accounts

The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables portfolio, which are pooled on a customer basis or country basis. In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three months ended March 31, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $0.4 million as of March 31, 2023 and $0.3 million as of December 31, 2022. Bad debt expense was immaterial for the three months ended March 31, 2023 and 2022.

Liability for sale of future royalties

On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI 42.933% (the “Assigned Royalty Payment”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Payments, RPI paid the Company $650.0 million in cash consideration. The Company has retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal $250.0 million in the aggregate as of March 31, 2023. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received $1.3 billion in respect of the Assigned Royalty Payments.

The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI. Refer to Note 9 for further details.

Indefinite-lived intangible assets

Indefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived

intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance.

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassess its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.

Income Taxes

The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.

On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended March 31, 2023.

Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. As a result of this tax law change, the Company recorded a federal and state tax provision for the three months ended March 31, 2023, in the amount of $0.7 million and $2.9 million, respectively.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.

On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible.

Leases

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.

Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.

Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.

A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.

The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.

Stock award plan

3 Months Ended

Mar. 31, 2023

Share-based Payment Arrangement [Abstract]

Stock award plan

8. Stock award plan

In May 2013, the Company’s Board of Directors and stockholders approved the 2013 Long-Term Incentive Plan, which became effective upon the closing of the Company’s initial public offering. On June 8, 2022 (the “Restatement Effective Date”), the Company’s stockholders approved the Amended and Restated 2013 Long-Term Incentive Plan (the “Amended 2013 LTIP”). The Amended 2013 LTIP provides for the grant of incentive stock options, nonstatutory stock options, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the Amended 2013 LTIP is the sum of (A) the number of shares of the Company’s common stock (up to 16,724,212 shares) that is equal to the sum of (1) the number of shares issued under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date, (2) the number of shares that remain available for issuance under the 2013 Long-Term

Incentive Plan immediately prior to the Restatement Effective Date and (3) the number of shares subject to awards granted under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date that are outstanding as of the Restatement Effective Date, plus (B) from and after the Restatement Effective Date, an additional 8,475,000 shares of Common Stock. As of March 31, 2023, awards for 6,598,348 shares of common stock are available for issuance under the Amended 2013 LTIP.

There are no additional shares of common stock available for issuance under the Company’s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan or 2013 Stock Incentive Plan.

In January 2020, the Company’s Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for, initially, up to at the time, an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company’s new hires’ employment compensation. In December 2020, the Company’s Board of Directors approved an additional 1,000,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan. In April 2022, the Company’s Board of Directors approved a reduction in the total number of shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan to 1,300,000 shares. In December 2022, the Company’s Board of Directors approved an additional 1,700,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan. As of March 31, 2023, awards for 1,699,326 shares of common stock were available for issuance under the 2020 Inducement Stock Incentive Plan.

The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company’s stock) of the fair market value of the common stock as of the date of grant; and (iv) the duration of the option (which, in the case of incentive stock options, may not exceed ten years). Options typically vest over a four-year period.

Inducement stock option awards

From January 1, 2023 through March 31, 2023, the Company issued a total of 863,410 stock options to various employees. Of those, 98,050 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

Stock option activity—A summary of stock option activity is as follows:


				Weighted-
		Weighted-		average		Aggregate
		average		remaining		intrinsic
	Number of	exercise		contractual		value(in
	options	price		term		thousands)

Outstanding at December 31, 2022	11,502,417	$	43.33
Granted	863,410	$	39.93
Exercised	(211,561)	$	28.61
Forfeited/Cancelled	(53,716)	$	52.25
Outstanding at March 31, 2023	12,100,550	$	43.30	6.38	years	$	102,959
Vested or Expected to vest at March 31, 2023	3,387,505	$	47.15	8.44	years	$	19,149
Exercisable at March 31, 2023	8,348,132	$	41.68	5.44	years	$	81,335

The fair value of grants made in the three months ended March 31, 2023 was contemporaneously estimated on the date of grant using the following assumptions:


		Three months ended

		March 31, 2023
Risk-free interest rate		3.54% - 3.88%
Expected volatility		54%
Expected term		5.5 years

The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the three months ended March 31, 2023 was $21.18 per share.

The expected term of options was estimated based on the Company’s historical exercise data and the expected volatility of options was estimated based on the Company’s historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.

Restricted Stock Awards and Restricted Stock Units—Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company’s shares on the grant date, are expensed over the vesting period. From January 1, 2023, through March 31, 2023, the Company issued a total of 1,861,235 restricted stock units to various employees. Of those, 42,755 were inducement grants for restricted stock units, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

The following table summarizes information on the Company’s restricted stock awards and units:


	Restricted Stock Awards and Units
		Weighted
		Average
		Grant
	Number of	Date
	Shares	Fair Value
Unvested at December 31, 2022	2,516,336	$	45.67
Granted	1,861,235		39.55
Vested	(701,066)		46.82
Forfeited	(26,763)		43.62
Unvested at March 31, 2023	3,649,742	$	42.34

Employee Stock Purchase Plan—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, “ESPP” or the "Plan”), for certain eligible employees. The Plan is administered by the Company’s Board of Directors or a committee appointed by the Company’s Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from one million shares to two million shares of the Company’s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company’s common stock at a purchase price of at least 85% of the closing price of a share of the Company’s common stock on the first business day of the offering period or the closing price of a share of the Company’s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company’s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three months ended March 31, 2023, the Company recorded $0.7 million in compensation expense related to the ESPP.

The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:


	Three Months Ended March 31,
	2023		2022
Research and development	$	15,314	$	13,034
Selling, general and administrative		13,501		13,555
Total	$	28,815	$	26,589

As of March 31, 2023, there was approximately $238.4 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s equity award plans. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 2.39 years.

Intangible assets and goodwill

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets and goodwill

12. Intangible assets and goodwill

Definite-lived intangibles

Definite lived intangible assets consisted of the following at March 31, 2023 and December 31, 2022:


		Ending Balance at				Reclass from				Foreign		Ending Balance at
Definite lived		December 31,				Indefinite Lived to				currency		March 31,
intangibles assets, gross		2022		Additions		Definite Lived		Impairment		translation		2023
Emflaza	$	420,253	$	17,515		—		—		—	$	437,768
Waylivra		9,316		—		—		—		170		9,486
Tegsedi		7,109		2,001		—		—		131		9,241
Upstaza		89,550		—		—		—		—		89,550
Total definite lived intangibles, gross	$	526,228	$	19,516	$	—	$	—	$	301	$	546,045


		Ending Balance at				Foreign		Ending Balance at
Definite lived		December 31,				currency		March 31,
intangibles assets, accumulated amortization		2022		Amortization		translation		2023
Emflaza	$	(266,023)	$	(36,996)	$	—	$	(303,019)
Waylivra		(2,751)		(261)		(52)		(3,064)
Tegsedi		(1,709)		(292)		(36)		(2,037)
Upstaza		(3,420)		(1,866)		—		(5,286)
Total definite lived intangibles, accumulated amortization	$	(273,903)	$	(39,415)	$	(88)	$	(313,406)

Total definite lived intangibles, net							$	232,639

Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increase the cost basis for the Emflaza rights intangible asset. For the three months ended March 31, 2023 and 2022, total milestone payments of $17.5 million and $62.1 million were recorded, respectively, which included a $50.0 million sales-based milestone during the three months ended March 31, 2022. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis. As of March 31, 2023, a milestone payable to Marathon of $17.5 million was recorded on the balance sheet within accounts payable and accrued expenses.

Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the three months ended March 31, 2023 and 2022, royalty payments of $2.0 million and $0.4 million, respectively, were recorded for Tegsedi. As of March 31, 2023, a royalty payable of $2.0 million for Tegsedi was recorded on the balance sheet within accounts payable and accrued expenses. No royalties for Waylivra have been triggered to date.

For the three months ended March 31, 2023 and 2022, the Company recognized amortization expense of $39.4 million and $23.5 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. The estimated future amortization of the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets is expected to be as follows:


	As of March 31, 2023
2023	$	118,266
2024		33,462
2025		9,702
2026		9,702
2027 and thereafter		61,507
Total	$	232,639

The weighted average remaining amortization period of the definite-lived intangibles as of March 31, 2023 is 5.0 years.

Indefinite-lived intangibles

Indefinite lived intangible assets consisted of the following at March 31, 2023 and December 31, 2022:


		Ending Balance at				Reclass from				Foreign		Ending Balance at
Indefinite lived		December 31,				Indefinite Lived to				currency		March 31,
intangibles assets		2022		Additions		Definite Lived		Impairment		translation		2023
Upstaza	$	235,766	$	—	$	—	$	—	$	—	$	235,766
PTC-FA		112,500		—		—		—		—		112,500
PTC-AS		105,300		—		—		—		—		105,300
Total indefinite lived intangibles	$	453,566	$	—	$	—	$	—	$	—	$	453,566

Total intangible assets, net											$	686,205

In connection with the acquisition of the Company’s gene therapy platform from Agilis, the Company acquired rights to Upstaza, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes PTC-FA, an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including PTC-AS for Angelman syndrome, a rare, genetic, neurological

disorder characterized by severe developmental delays. As of March 31, 2023, there have been no changes to the indefinite lived intangible assets balance since the year ended December 31, 2022.

Goodwill

As a result of the Agilis Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. As of March 31, 2023, there have been no changes to the balance of goodwill since the date of the Agilis Merger. Accordingly, the goodwill balance as of March 31, 2023 is $82.3 million.

Intangible assets and goodwill - Definite-lived Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Definite-lived intangible assets
Milestone Payable	$ 32,500
Accrued royalties	32,694		$ 40,546
Definite-lived intangibles
Amortization	(39,415)	$ (23,473)
Finite-Lived Intangible Assets, Net	$ 232,639
Weighted Average
Definite-lived intangible assets
Remaining amortization period	5 years
Emflaza asset acquisition
Definite-lived intangible assets
Milestone obligation payments recorded	$ 17,500	62,100
Emflaza asset acquisition \| Accounts payable and accrued expenses
Definite-lived intangible assets
Milestone Payable	17,500
Emflaza asset acquisition \| Sales Milestones
Definite-lived intangible assets
Milestone obligation payments recorded		50,000
Akcea \| Waylivra
Definite-lived intangible assets
Royalty payments	0
Akcea \| Tegsedi
Definite-lived intangible assets
Royalty payments	2,000	$ 400
Akcea \| Tegsedi \| Accounts payable and accrued expenses
Definite-lived intangible assets
Accrued royalties	2,000
Definite-lived intangible assets
Definite-lived intangibles
Beginning balance - Definite-lived assets, Gross	526,228
Additions	19,516
Foreign Currency Translation	301
Ending balance - Definite-lived assets, Gross	546,045
Beginning balance - Accumulated amortization	(273,903)
Amortization	(39,415)
Foreign Currency Translation - Accumulated amortization	(88)
Ending balance - Accumulated amortization	(313,406)
Finite-Lived Intangible Assets, Net	232,639
Definite-lived intangible assets \| Emflaza
Definite-lived intangibles
Beginning balance - Definite-lived assets, Gross	420,253
Additions	17,515
Ending balance - Definite-lived assets, Gross	437,768
Beginning balance - Accumulated amortization	(266,023)
Amortization	(36,996)
Ending balance - Accumulated amortization	(303,019)
Definite-lived intangible assets \| Waylivra
Definite-lived intangibles
Beginning balance - Definite-lived assets, Gross	9,316
Foreign Currency Translation	170
Ending balance - Definite-lived assets, Gross	9,486
Beginning balance - Accumulated amortization	(2,751)
Amortization	(261)
Foreign Currency Translation - Accumulated amortization	(52)
Ending balance - Accumulated amortization	(3,064)
Definite-lived intangible assets \| Tegsedi
Definite-lived intangibles
Beginning balance - Definite-lived assets, Gross	7,109
Additions	2,001
Foreign Currency Translation	131
Ending balance - Definite-lived assets, Gross	9,241
Beginning balance - Accumulated amortization	(1,709)
Amortization	(292)
Foreign Currency Translation - Accumulated amortization	(36)
Ending balance - Accumulated amortization	(2,037)
Definite-lived intangible assets \| Upstaza
Definite-lived intangibles
Beginning balance - Definite-lived assets, Gross	89,550
Ending balance - Definite-lived assets, Gross	89,550
Beginning balance - Accumulated amortization	(3,420)
Amortization	(1,866)
Ending balance - Accumulated amortization	$ (5,286)

Stock award plan - (Tables)

3 Months Ended

Mar. 31, 2023

Share-based Payment Arrangement [Abstract]

Summary of stock option activity


				Weighted-
		Weighted-		average		Aggregate
		average		remaining		intrinsic
	Number of	exercise		contractual		value(in
	options	price		term		thousands)

Outstanding at December 31, 2022	11,502,417	$	43.33
Granted	863,410	$	39.93
Exercised	(211,561)	$	28.61
Forfeited/Cancelled	(53,716)	$	52.25
Outstanding at March 31, 2023	12,100,550	$	43.30	6.38	years	$	102,959
Vested or Expected to vest at March 31, 2023	3,387,505	$	47.15	8.44	years	$	19,149
Exercisable at March 31, 2023	8,348,132	$	41.68	5.44	years	$	81,335

Schedule of assumptions used to estimate fair values of grants made on the date of grant


		Three months ended

		March 31, 2023
Risk-free interest rate		3.54% - 3.88%
Expected volatility		54%
Expected term		5.5 years

Summary of information on the Company's restricted stock


	Restricted Stock Awards and Units
		Weighted
		Average
		Grant
	Number of	Date
	Shares	Fair Value
Unvested at December 31, 2022	2,516,336	$	45.67
Granted	1,861,235		39.55
Vested	(701,066)		46.82
Forfeited	(26,763)		43.62
Unvested at March 31, 2023	3,649,742	$	42.34

Schedule of share-based compensation expense recorded in the statement of operations


	Three Months Ended March 31,
	2023		2022
Research and development	$	15,314	$	13,034
Selling, general and administrative		13,501		13,555
Total	$	28,815	$	26,589

Leases - (Tables)

3 Months Ended

Mar. 31, 2023

Leases

Schedule of lease costs


	Three Months Ended		Three Months Ended
		March 31, 2023		March 31, 2022
Operating Lease Cost
Fixed lease cost	$	5,473	$	4,126
Variable lease cost		1,353		1,076
Short-term lease cost		303		74
Total operating lease cost	$	7,129	$	5,276


	March 31, 2023		December 31, 2022
Weighted-average remaining lease terms - operating leases (years)	11.57		11.61
Weighted-average discount rate - operating leases	8.63	%	8.61	%
Weighted-average remaining lease terms - finance lease (years)	9.76		10.01
Weighted-average discount rate - finance lease	7.80	%	7.80	%

Schedule of supplemental cash flow information related to leases


	Three Months Ended March 31,
	2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,811	$	3,411
Financing cash flows from finance lease		1,379		1,276
Operating cash flows from finance leases		1,621		1,724

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	—	$	587

Schedule of future lease payments - Operating leases


	Operating Leases		Finance Lease
2023 (excludes the three months ended March 31, 2023)	$	11,575	$	—
2024		18,465		3,000
2025		20,434		3,000
2026		19,986		3,000
2027 and thereafter		193,792		18,000
Total lease payments		264,252		27,000
Less: Imputed Interest expense		154,212		7,959
Total	$	110,040	$	19,041

Schedule of future lease payments - Finance leases


	Operating Leases		Finance Lease
2023 (excludes the three months ended March 31, 2023)	$	11,575	$	—
2024		18,465		3,000
2025		20,434		3,000
2026		19,986		3,000
2027 and thereafter		193,792		18,000
Total lease payments		264,252		27,000
Less: Imputed Interest expense		154,212		7,959
Total	$	110,040	$	19,041

Leases

3 Months Ended

Mar. 31, 2023

Leases

Leases

3. Leases

The Company leases office space in South Plainfield, New Jersey for its principal office under two noncancelable operating leases through August 2024, in addition to office and laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers.

The Company also leases approximately 220,500 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the “Hopewell Lease”) with Hopewell Campus Owner LLC. The rental term of the Hopewell Lease commenced on July 1, 2020 and has an initial term of fifteen

years (the “Hopewell Initial Term”), with two consecutive ten year renewal periods, each at the Company’s option. The aggregate rent for the Hopewell Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Hopewell Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Hopewell Lease contains customary events of default, representations, warranties and covenants.

In May 2022, the Company entered into a Lease Agreement (the “Warren Lease”) with Warren CC Acquisitions, LLC (the “Warren Landlord”) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the “Warren Premises”) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the “Warren Initial Term”), followed by three consecutive five-year renewal periods at the Company’s option. The aggregate base rent for the Warren Initial Term will be approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company will be entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Company’s total base rent obligation to $144.4 million. The rental rate for the renewal periods will be at the Fair Market Rental Value (as defined in the Warren Lease) and determined at the time of the exercise of the renewal. Beginning in the second lease year, the Company is also responsible for the payment of all taxes and operating expenses for the Warren Premises. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date.

The Company plans on developing the Warren Premises into office and laboratory space. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at Commencement Date. In connection with the execution of the Warren Lease, the Company also committed to fund a construction account with $3.6 million to go towards the Company’s improvements of the Warren Premises. Subject to the terms of the Warren Lease, the Company has a right of first offer to purchase the Warren Premises if the Warren Landlord receives a bona fide third party offer to purchase the Warren Premises or the Warren Landlord decides to sell the Warren Premises

On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The Company determined that the agreement was a finance lease, for which the Company recorded a finance lease ROU asset for $41.4 million and corresponding finance lease liability for $41.4 million at the onset of the lease agreement. Given that the leased asset is designed for the production of PTC’s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730. Accordingly, the full $41.4 million relating to the finance lease ROU asset was written off and expensed to research and development during the year ended December 31, 2020. As of March 31, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $1.8 million and $17.2 million, respectively, and are directly related to the Company’s MassBio agreement. As of December 31, 2022, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $18.7 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $0.4 million related to interest on the lease liability during the three months ended March 31, 2023 and 2022, respectively.

The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company’s leases have remaining operating lease terms ranging from 0.9 years to 16.2 years and certain of the leases include renewal options to extend the lease for up to 20 years. Rent expense was $7.1 million and $5.3 million for the three months ended March 31, 2023 and 2022, respectively.

The components of operating lease expense were as follows:


	Three Months Ended		Three Months Ended
		March 31, 2023		March 31, 2022
Operating Lease Cost
Fixed lease cost	$	5,473	$	4,126
Variable lease cost		1,353		1,076
Short-term lease cost		303		74
Total operating lease cost	$	7,129	$	5,276

Total operating lease cost is a component of operating expenses on the consolidated statements of operations.

Supplemental lease term and discount rate information related to leases was as follows as March 31, 2023 and December 31, 2022:


	March 31, 2023		December 31, 2022
Weighted-average remaining lease terms - operating leases (years)	11.57		11.61
Weighted-average discount rate - operating leases	8.63	%	8.61	%
Weighted-average remaining lease terms - finance lease (years)	9.76		10.01
Weighted-average discount rate - finance lease	7.80	%	7.80	%

Supplemental cash flow information related to leases was as follows as of March 31, 2023 and 2022:


	Three Months Ended March 31,
	2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,811	$	3,411
Financing cash flows from finance lease		1,379		1,276
Operating cash flows from finance leases		1,621		1,724

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	—	$	587

Future minimum lease payments under non-cancelable leases as of March 31, 2023 were as follows:


	Operating Leases		Finance Lease
2023 (excludes the three months ended March 31, 2023)	$	11,575	$	—
2024		18,465		3,000
2025		20,434		3,000
2026		19,986		3,000
2027 and thereafter		193,792		18,000
Total lease payments		264,252		27,000
Less: Imputed Interest expense		154,212		7,959
Total	$	110,040	$	19,041

Debt - (Tables)

3 Months Ended

Mar. 31, 2023

Debt Instrument, Redemption [Line Items]

Summary of liability for sale of future royalties


	Three Months Ended March 31,
Liability for sale of future royalties- (current and noncurrent)	2023
Beginning balance as of December 31, 2022	$	757,886
Less: Non-cash royalty revenue payable to RPI		(13,237)
Plus: Non-cash interest expense recognized		18,902
Ending balance	$	763,551
Effective interest rate as of March 31, 2023		9.8	%

1.50% Convertible senior notes due 2026

Debt Instrument, Redemption [Line Items]

Summary of convertible notes



	March 31, 2023		December 31, 2022
Principal	$	287,500	$	287,500
Less: Debt issuance costs		(4,168)		(4,456)
Net carrying amount	$	283,332	$	283,044

Summary of interest expense recognized related to the Convertible Notes



	Three Months Ended March 31,
	2023			2022
Contractual interest expense	$	1,069		$	1,069
Amortization of debt issuance costs		288			283
Total	$	1,357		$	1,352
Effective interest rate		1.9	%		1.9	%

3.00% Convertible senior notes due 2022

Debt Instrument, Redemption [Line Items]

Summary of interest expense recognized related to the Convertible Notes



	Three Months Ended March 31,
	2023			2022
Contractual interest expense	$	—		$	1,110
Amortization of debt issuance costs		—			181
Total	$	—		$	1,291
Effective interest rate		—	%		3.5	%

Senior Secured Term Loan Facility

Debt Instrument, Redemption [Line Items]

Summary of interest expense recognized related to debt


	Three Months Ended
	March 31,
	2023
Contractual interest expense	$	9,178
Amortization of debt issuance costs		150
Total	$	9,328
Effective interest rate		13.2	%

Summary of significant accounting policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of presentation

Use of estimates

Restricted Cash

Restricted cash


	End of			Beginning of
	period-		period-
	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	167,495	$	279,834
Restricted cash noncurrent included in deposits and other assets		16,099		16,091
Restricted cash current included in prepaid expenses and other current assets		50,000		—
Total Cash, cash equivalents and restricted cash per statement of cash flows	$	233,594	$	295,925

Marketable securities

Inventory and cost of product sales

Inventory

The following table summarizes the components of the Company’s inventory for the periods indicated:


	March 31, 2023		December 31, 2022
Raw materials	$	1,097	$	1,078
Work in progress		18,438		14,074
Finished goods		7,114		6,656
Total inventory	$	26,649	$	21,808

Cost of product sales

Revenue recognition

Net product revenue

Collaboration and royalty revenue

For the three months ended March 31, 2023 and 2022, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial.

For the three months ended March 31, 2023 and 2022, the Company has recognized $30.8 million and $18.9 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

Allowance for doubtful accounts

Liability for sale of future royalties

Indefinite-lived intangible assets

Goodwill

Income Taxes

Leases

Debt - Narrative (Details)		1 Months Ended		3 Months Ended	18 Months Ended
Debt - Narrative (Details)	Aug. 15, 2022 USD ($)	Apr. 30, 2022 USD ($)	Sep. 30, 2019 USD ($) D $ / shares	Mar. 31, 2023 USD ($)	Mar. 14, 2022	Dec. 31, 2022 USD ($)	Aug. 31, 2015 USD ($)
Long-term debt
Long-term debt				$ 572,091,000		$ 571,722,000
Additional paid-in capital				$ 2,339,886,000		2,305,020,000
1.50% Convertible senior notes due 2026
Long-term debt
Interest rate ( as a percent )				1.50%
Incremental interest rate per annum					0.50%
Additional interest paid		$ 2,100,000
Convertible debt \| 1.50% Convertible senior notes due 2026
Long-term debt
Net carrying amount				$ 283,332,000		283,044,000
Debt principal amount			$ 287,500,000	$ 287,500,000		$ 287,500,000
Debt instrument additional amount available for repurchase			$ 37,500,000
Interest rate ( as a percent )			1.50%	1.50%
Net proceeds from issuance of convertible notes			$ 279,300,000
Trading days, number \| D			20
Consecutive trading days, period \| D			30
Stock price trigger			130.00%
Business days, period			5 days
Consecutive trading-day period			5 days
Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day			98.00%
Conversion ratio			19.0404
Conversion price per share (in dollars per share) \| $ / shares			$ 52.52
Redemption price as percent of principal amount			100.00%
Convertible instruments principal and unpaid interest payable upon events of default			100.00%
Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default			25.00%
Term of the convertible notes				3 years 6 months
Convertible debt \| 1.50% Convertible senior notes due 2026 \| Redemption on or after September 20, 2023
Long-term debt
Trading days, number \| D			19
Consecutive trading days, period \| D			30
Stock price trigger			130.00%
Redemption price as percent of principal amount			100.00%
Sinking fund			$ 0
Convertible debt \| 3.00% Convertible senior notes due 2022
Long-term debt
Debt principal amount							$ 150,000,000.0
Interest rate ( as a percent )							3.00%
Repayment of convertible notes including accrued interest	$ 152,300,000

Intangible assets and goodwill - Goodwill (Details) - USD ($) $ in Thousands	55 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Aug. 23, 2018
Goodwill
Goodwill	$ 82,341	$ 82,341
Changes in goodwill	$ 0
Agilis
Goodwill
Goodwill			$ 82,300

Revenue recognition - Net Product Sales (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment country Distributor	Mar. 31, 2022 USD ($) segment country Distributor
Revenue recognition
Number of operating segments \| segment	1	1
Revenue	$ 220,382	$ 148,735
Net product revenue \| Geographic concentration risk
Revenue recognition
Number of countries exceeding 10% of net product sales \| country	3	2
Percentage of net product sales threshold	10.00%	10.00%
Net product revenue \| Geographic concentration risk \| United States
Revenue recognition
Revenue	$ 54,600	$ 48,600
Net product revenue \| Geographic concentration risk \| Russia
Revenue recognition
Revenue	44,600
Net product revenue \| Geographic concentration risk \| Brazil
Revenue recognition
Revenue	$ 25,900	$ 25,800
Net product revenue \| Customer concentration risk
Revenue recognition
Number of distributors \| Distributor	2	2
Net product revenue \| Customer concentration risk \| Minimum
Revenue recognition
Percentage of net product sales threshold	10.00%	10.00%
Net product revenue
Revenue recognition
Revenue	$ 187,557	$ 129,832
Net product revenue \| Non-US
Revenue recognition
Revenue	133,000	81,200
Emflaza \| United States
Revenue recognition
Revenue	54,600	48,600
Translarna \| Non-US
Revenue recognition
Revenue	$ 115,100	$ 79,200

Fair value of financial instruments and investments - Marketable Securities (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2020 USD ($) $ / shares	Mar. 31, 2023 USD ($) fund	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Equity Investments
Net unrealized gain (loss) on equity investments		$ 2,166	$ (6,477)
Redemption of marketable securities- equity investments		2,196	2,423
ClearPoint Convertible note
Purchase of convertible note			39,035
Unrealized gain (loss) on convertible note		59	(1,542)
ClearPoint equity investment
Equity Investments
Net unrealized gain (loss) on equity investments		(100)	(1,000)
ClearPoint equity investment \| Quoted prices in active markets for identical assets (Level 1)
Equity Investments
Fair value of equity investment		10,900		$ 11,000
ClearPoint convertible debt
ClearPoint Convertible note
Purchase of convertible note	$ 10,000
Conversion price - convertible note \| $ / shares	$ 6.00
Term of convertible note	5 years
Unrealized gain (loss) on convertible note		100	(1,500)
ClearPoint convertible debt \| Recurring basis \| Significant other observable inputs (Level 2) \| Deposits and Other Assets, Noncurrent
ClearPoint Convertible note
ClearPoint convertible debt security		$ 15,300		$ 15,200
Mutual Funds
Equity Investments
Number of mutual funds denominated in a foreign currency \| fund		1
Net unrealized gain (loss) on equity investments		$ 2,200	(6,500)
Redemption of marketable securities- equity investments		2,200	2,400
Unrealized foreign currency gains (losses) on equity investments		$ 300	$ 700

Stock award plan - Assumptions Used (Details)	3 Months Ended
Stock award plan - Assumptions Used (Details)	Mar. 31, 2023
Valuation assumptions
Expected term (in years)	5 years 6 months
Stock option
Valuation assumptions
Expected volatility (as a percent)	54.00%
Stock option \| Minimum
Valuation assumptions
Risk-free interest rate (as a percent)	3.54%
Stock option \| Maximum
Valuation assumptions
Risk-free interest rate (as a percent)	3.88%

Revenue recognition - Collaboration and Royalty Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Nov. 30, 2011
Revenue recognition
Remaining potential milestones that can be achieved	$ 250,000
Revenue	220,382	$ 148,735
Collaboration revenue
Revenue recognition
Revenue	6	7
Royalty revenue
Revenue recognition
Revenue	30,831	18,896
SMA License Agreement \| Royalty revenue
Revenue recognition
Revenue	30,800	$ 18,900
Research And Development Event Milestones \| SMA License Agreement
Revenue recognition
Remaining potential milestones that can be achieved	0
Sales Milestones \| SMA License Agreement
Revenue recognition
Remaining potential milestones that can be achieved	$ 250,000
Maximum \| Research And Development Event Milestones \| SMA License Agreement
Revenue recognition
Remaining potential milestones that can be achieved			$ 135,000
Maximum \| Sales Milestones \| SMA License Agreement
Revenue recognition
Remaining potential milestones that can be achieved			$ 325,000

Fair value of financial instruments and investments - Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financial assets and liabilities measured at fair value on recurring basis
Marketable securities - available for sale	$ 10,249	$ 22,610
Contingent consideration payable	166,400	164,000
Transfers of assets measured between Level 1, Level 2, and Level 3	0	0
Recurring basis
Financial assets and liabilities measured at fair value on recurring basis
ClearPoint Equity Investments	10,926	10,965
ClearPoint convertible debt security	15,290	15,231
Recurring basis \| Quoted prices in active markets for identical assets (Level 1)
Financial assets and liabilities measured at fair value on recurring basis
ClearPoint Equity Investments	10,926	10,965
Recurring basis \| Significant other observable inputs (Level 2)
Financial assets and liabilities measured at fair value on recurring basis
ClearPoint convertible debt security	15,290	15,231
Recurring basis \| Development and Regulatory Milestones
Financial assets and liabilities measured at fair value on recurring basis
Contingent consideration payable	85,500	82,500
Recurring basis \| Development and Regulatory Milestones \| Significant unobservable inputs (Level 3)
Financial assets and liabilities measured at fair value on recurring basis
Contingent consideration payable	85,500	82,500
Recurring basis \| Net Sales Milestones and Royalties
Financial assets and liabilities measured at fair value on recurring basis
Contingent consideration payable	80,900	81,500
Recurring basis \| Net Sales Milestones and Royalties \| Significant unobservable inputs (Level 3)
Financial assets and liabilities measured at fair value on recurring basis
Contingent consideration payable	80,900	81,500
Recurring basis \| Marketable securities
Financial assets and liabilities measured at fair value on recurring basis
Marketable securities - available for sale	10,249	22,610
Marketable securities - equity investments	108,559	108,261
Recurring basis \| Marketable securities \| Quoted prices in active markets for identical assets (Level 1)
Financial assets and liabilities measured at fair value on recurring basis
Marketable securities - equity investments	108,559	108,261
Recurring basis \| Marketable securities \| Significant other observable inputs (Level 2)
Financial assets and liabilities measured at fair value on recurring basis
Marketable securities - available for sale	$ 10,249	$ 22,610

The Company (Details) $ in Thousands	3 Months Ended
The Company (Details) $ in Thousands	Mar. 31, 2023 USD ($) product	Dec. 31, 2022 USD ($)
Long-term debt
Number of products \| product	2
Retained earnings (accumulated deficit) \| $	$ (2,795,933)	$ (2,656,974)
1.50% Convertible senior notes due 2026
Long-term debt
Interest rate ( as a percent )	1.50%

Leases - Cash flow (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Cash flow (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating cash flows from operating leases	$ 3,811	$ 3,411
Financing cash flows from finance lease	1,379	1,276
Operating cash flows from finance leases	$ 1,621	1,724
Right-of-use assets obtained in exchange for operating lease obligations		$ 587

Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Collaboration and royalty revenue
Revenue	$ 220,382	$ 148,735
Collaboration and grant revenue
Collaboration and royalty revenue
Revenue	6	7
Royalty revenue
Collaboration and royalty revenue
Revenue	30,831	18,896
SMA License Agreement \| Royalty revenue
Collaboration and royalty revenue
Revenue	$ 30,800	$ 18,900

Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) - USD ($) $ in Millions		1 Months Ended
	Jul. 17, 2020	Jul. 31, 2020	Mar. 31, 2023
Assigned royalty payments
Cash consideration received from Royalty Purchase Agreement		$ 650.0
Assigned royalty payment, retained percentage	57.067%
Remaining potential milestones that can be achieved			$ 250.0
Royalty Purchase Agreement \| Assigned Royalty Payments
Assigned royalty payments
Assigned royalty payment, percentage	42.933%
Cash consideration received from Royalty Purchase Agreement	$ 650.0
Royalty purchase agreement, termination period	60 days
Royalty purchase agreement, payment maximum	$ 1,300.0

Accounts payable and accrued expenses - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee compensation, benefits, and related accruals	$ 36,417	$ 62,669
Income tax payable	5,730	4,712
Consulting and contracted research	22,547	38,882
Professional fees	4,216	3,093
Sales allowance	68,136	63,787
Sales rebates	94,296	67,355
Royalties	32,694	40,546
Accounts payable	26,311	27,268
Milestone payable	32,500
Other	9,244	12,054
Accounts payable and accrued expenses	$ 332,091	$ 320,366

Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) - Significant unobservable inputs (Level 3) - Agilis - Commitments - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Development and Regulatory Milestones
Changes in the fair value of warrant liability and SARs liability
Beginning Balance	$ 82,500	$ 139,300
Additions	0	0
Change in fair value	3,000	(4,600)
Rights Exchange settlement	0	0
Ending Balance	85,500	134,700
Net Sales Milestones and Royalties
Changes in the fair value of warrant liability and SARs liability
Beginning Balance	81,500	100,600
Additions	0	0
Change in fair value	(600)	(7,100)
Rights Exchange settlement	0	0
Ending Balance	$ 80,900	$ 93,500

Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) - Agilis - Commitments $ in Thousands	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Development and Regulatory Milestone \| Minimum
Fair Value Valuation Inputs
Potential milestones	$ 0	$ 0
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Development and Regulatory Milestone \| Maximum
Fair Value Valuation Inputs
Potential milestones	$ 331,000	$ 331,000
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Probability of Success \| Minimum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.25	0.25
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Probability of Success \| Maximum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.92	0.92
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Probability of Success \| Weighted Average
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.35
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Discount Rate \| Minimum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.055	0.062
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Discount Rate \| Maximum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.077	0.083
Development and Regulatory Milestones \| Valuation Technique, Discounted Cash Flow \| Measurement Input, Discount Rate \| Weighted Average
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.072
Development and Regulatory Milestones \| Significant unobservable inputs (Level 3)
Fair Value Valuation Inputs
Fair value	$ 85,500	$ 82,500	$ 134,700	$ 139,300
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Sales Milestones \| Minimum
Fair Value Valuation Inputs
Potential milestones	0	0
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Sales Milestones \| Maximum
Fair Value Valuation Inputs
Potential milestones	$ 150,000	$ 150,000
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Probability of Success \| Minimum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.25	0.25
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Probability of Success \| Maximum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	1	1
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Probability of Success \| Weighted Average
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.50
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Percentage of Sales for Royalties \| Minimum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.02	0.02
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Percentage of Sales for Royalties \| Maximum
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.06	0.06
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Measurement Input, Discount Rate
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.12	0.115
Net Sales Milestones and Royalties \| Valuation Technique, Option Pricing Model \| Measurement Input, Discount Rate \| Weighted Average
Fair Value Valuation Inputs
Rights Exchange Settlement measurement	0.120
Net Sales Milestones and Royalties \| Significant unobservable inputs (Level 3)
Fair Value Valuation Inputs
Fair value	$ 80,900	$ 81,500	$ 93,500	$ 100,600

Intangible assets and goodwill - Future Amortization (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 118,266
2024	33,462
2025	9,702
2026	9,702
2027 and thereafter	61,507
Total	$ 232,639

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares (in shares)	250,000,000	250,000,000
Common stock, issued shares (in shares)	74,012,034	73,104,692
Common stock, outstanding shares (in shares)	74,012,034	73,104,692

Leases - Lease payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating leases
2023 (excludes the three months ended March 31, 2023)	$ 11,575
2024	18,465
2025	20,434
2026	19,986
2027 and thereafter	193,792
Total lease payments	264,252
Less: Imputed Interest expense	154,212
Total	110,040
Finance leases
2024	3,000
2025	3,000
2026	3,000
2027 and thereafter	18,000
Total lease payments	27,000
Less: Imputed Interest expense	7,959
Total	$ 19,041

Fair value of financial instruments and investments - Available-for-sale securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Securities in an unrealized loss position greater than 12 months - Unrealized losses	$ (440)	$ (499)
Securities in an unrealized loss position greater than 12 months - Fair Value	10,249	10,186
Total - Unrealized losses	(440)	(499)
Total - Fair Value	10,249	10,186
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Securities in an unrealized loss position greater than 12 months - Unrealized losses	(440)	(499)
Securities in an unrealized loss position greater than 12 months - Fair Value	10,249	10,186
Total - Unrealized losses	(440)	(499)
Total - Fair Value	$ 10,249	$ 10,186

Stock award plan - Restricted Stock (Details) - Restricted stock awards and units	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of Shares
Balance at the beginning of the period (in shares) \| shares	2,516,336
Granted (in shares) \| shares	1,861,235
Vested (in shares) \| shares	(701,066)
Forfeited (in shares) \| shares	(26,763)
Balance at the end of the period (in shares) \| shares	3,649,742
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per share) \| $ / shares	$ 45.67
Granted (in dollars per share) \| $ / shares	39.55
Vested (in dollars per share) \| $ / shares	46.82
Forfeited (in dollars per share) \| $ / shares	43.62
Balance at the end of the period (in dollars per share) \| $ / shares	$ 42.34

Capitalization - Narrative (Details) - Sales Agreement - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Aug. 31, 2019
Common stock
Number of shares issued in transaction (in shares)	0	0
Maximum
Common stock
Value of shares available to be issued and sold in transaction			$ 125.0
Aggregate value of remaining shares to be issued and sold	$ 93.0

Leases - Lease costs (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Lease costs (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Leases
Fixed lease cost	$ 5,473	$ 4,126
Variable lease cost	1,353	1,076
Short-term lease cost	303	74
Total operating lease cost	$ 7,129	$ 5,276

Intangible assets and goodwill - Indefinite-lived Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Indefinite-lived intangibles
Intangible assets, net	$ 686,205	$ 705,891
Change in indefinite-lived intangibles	0
Indefinite-lived intangible assets
Indefinite-lived intangibles
Beginning Balance	453,566
Additions
Ending Balance	453,566
Intangible assets, net	686,205
Indefinite-lived intangible assets \| Upstaza
Indefinite-lived intangibles
Beginning Balance	235,766
Additions
Ending Balance	235,766
Indefinite-lived intangible assets \| PTC-FA
Indefinite-lived intangibles
Beginning Balance	112,500
Additions
Ending Balance	112,500
Indefinite-lived intangible assets \| PTC-AS
Indefinite-lived intangibles
Beginning Balance	105,300
Additions
Ending Balance	$ 105,300

Leases - Supplemental lease terms (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases
Weighted-average remaining lease terms - operating leases (years)	11 years 6 months 25 days	11 years 7 months 9 days
Weighted-average discount rate - operating leases	8.63%	8.61%
Weighted-average remaining lease terms - finance lease (years)	9 years 9 months 3 days	10 years 3 days
Weighted-average discount rate - finance lease	7.80%	7.80%

Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Marketable securities, Less Than 12 Months	$ 10,249	$ 12,424
Marketable securities, More Than 12 Months		10,186
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Marketable securities, Less Than 12 Months		12,424
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Marketable securities, Less Than 12 Months	$ 10,249
Marketable securities, More Than 12 Months		$ 10,186

Revenue recognition - Performance Obligations (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Remaining Performance Obligation
Remaining performance obligations	$ 0.2	$ 1.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Remaining Performance Obligation
Remaining performance obligations	$ 0.2
Revenue, performance obligation, period	1 year

Net loss per share - Antidilutive (Details) - shares	3 Months Ended
Net loss per share - Antidilutive (Details) - shares	Mar. 31, 2023	Mar. 31, 2022
Net loss per share
Total shares excluded from calculation (in shares)	15,750,292	14,266,694
Stock Options
Net loss per share
Total shares excluded from calculation (in shares)	12,100,550	11,751,713
Restricted Stock and Restricted Stock Units [Member]
Net loss per share
Total shares excluded from calculation (in shares)	3,649,742	2,514,981